StreetInsider.com News Articles

Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB

Thu, 22 Oct 2026 08:30:00 -0400

NEW HOPE, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it will host an R&D Day on November 12th, 2026, at 3:00pm ET in New York City. The event will also be available via live webcast.

Orchestra BioMed leadership will be joined by key leading cardiologists to discuss the clinical and treatment burden associated with uncontrolled hypertension in pacemaker-indicated patients and restenosis in coronary stent interventions, as well as the potential

Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB

Thu, 22 Oct 2026 08:30:00 -0400

Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB

Thu, 22 Oct 2026 08:30:00 -0400

Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB

Thu, 22 Oct 2026 08:30:00 -0400

Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB

Thu, 22 Oct 2026 08:30:00 -0400

Company leadership, leading cardiologists and trial investigators to discuss unmet patient needs, BACKBEAT and Virtue pivotal trials, and upcoming milestones; in person in New York City and via live webcast

NEW HOPE, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it will host an R&D Day on November 12^th, 2026, at 3:00pm ET in New York City. The event will also be available via live webcast.

Orchestra BioMed leadership will be joined

Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB

Thu, 22 Oct 2026 08:30:00 -0400

NEW HOPE, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it will host an R&D Day on November 12^th, 2026, at 3:00pm ET in New York City. The event will also be available via live webcast.

Orchestra BioMed leadership will be joined

Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB

Thu, 22 Oct 2026 08:30:00 -0400

NEW HOPE, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it will host an R&D Day on November 12^th, 2026, at 3:00pm ET in New York City. The event will also be available via live webcast.

Orchestra BioMed leadership will be joined

Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB

Thu, 22 Oct 2026 08:30:00 -0400

NEW HOPE, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it will host an R&D Day on November 12^th, 2026, at 3:00pm ET in New York City. The event will also be available via live webcast.

Orchestra BioMed leadership will be joined

OpenAI acquires Orchestra Bio to boost drug development AI, Axios reports

Tue, 20 Oct 2026 14:09:31 -0400

Investing.com -- OpenAI has acquired Orchestra Bio, a startup that builds AI agents to help pharmaceutical companies manage drug development, Axios reported on Tuesday .

OpenAI will integrate Orchestra's team and technology into Rosalind, its suite of AI models and tools designed for life sciences researchers. Financial terms of the acquisition were not disclosed.

Orchestra's platform allows scientists to delegate tasks like monitoring studies, tracking drug development timelines and identifying potential delays to AI agents. Both companies aim to deploy agents that can connect scientific findings with the decisions and next steps required to advance potential treatments.

OpenAI introduced its

OpenAI acquires Orchestra Bio to boost drug development AI, Axios reports

Tue, 20 Oct 2026 14:09:31 -0400

Investing.com -- OpenAI has acquired Orchestra Bio, a startup that builds AI agents to help pharmaceutical companies manage drug development, Axios reported on Tuesday .

OpenAI will integrate Orchestra's team and technology into Rosalind, its suite of AI models and tools designed for life sciences researchers. Financial terms of the acquisition were not disclosed.

OpenAI introduced its

OpenAI acquires Orchestra Bio to boost drug development AI, Axios reports

Tue, 20 Oct 2026 14:09:31 -0400

Investing.com -- OpenAI has acquired Orchestra Bio, a startup that builds AI agents to help pharmaceutical companies manage drug development, Axios reported on Tuesday .

OpenAI will integrate Orchestra's team and technology into Rosalind, its suite of AI models and tools designed for life sciences researchers. Financial terms of the acquisition were not disclosed.

OpenAI introduced its

Piper Sandler: 'We believe investors should start to look at and build positions in Orchestra BioMed (OBIO)'

Thu, 15 Oct 2026 08:58:04 -0400

Piper Sandler analyst Matt O'Brien reiterated an Overweight rating and $12.00 price target on Orchestra BioMed Inc. (NASDAQ: OBIO).

The analyst commented: "We wanted to highlight OBIO as a name that could drive significant value creation for shareholders in the coming quarters. Its key AVIM therapy to treat hypertension patients recently completed enrollment in its pivotal trial, with a data release in Q2’27 (likely HRS). If positive, which we believe it will be, it could lead to approval for this unique therapy in early ’28 (though we believe the stock will move on the data). AVIM revenue (global) to OBIO could

H.C. Wainwright Reiterates Buy Rating on Orchestra BioMed Inc. (OBIO)

Mon, 05 Oct 2026 06:49:47 -0400

H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $10.00 price target on Orchestra BioMed Inc. (NASDAQ: OBIO).

The analyst commented: "Yesterday, Orchestra Biomed announced that the BACKBEAT global pivotal trial of the atrioventricular interval modulation (AVIM) therapy in pacemaker-indicated patients with uncontrolled hypertension has surpassed full enrollment target of 316 randomized patients. As of September 30, 2026, 330 patients have been randomized at 81 sites across 13 countries. Approved by the FDA, the trial protocol specifies 284 evaluable randomized subjects for the primary endpoint analysis with a total enrollment target of 316 patients to account for potential loss to

Form 4 Orchestra BioMed Holding For: Oct 01 Filed by: Sherman Darren

Fri, 02 Oct 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20261002/27142860.html

Form 144 Orchestra BioMed Holding Filed by: Sherman Darren

Thu, 01 Oct 2026 10:37:00 -0400

si-local-file:///var/storage/secattach/20261001/27133495.html

Form 8-K Orchestra BioMed Holding For: Oct 01

Thu, 01 Oct 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20261001/27131989.html

Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy

Thu, 01 Oct 2026 08:00:00 -0400

330 patients randomized as of September 30, 2026, surpassing full trial enrollment target
Company reiterates prior guidance: primary endpoint data to be submitted for late-breaking presentation consideration at a major cardiovascular conference in Q2 2027
Data expected to support future marketing application submissions by Medtronic to the FDA and other global regulatory agencies

NEW HOPE, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading medical device companies, today announced that it

Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy

Thu, 01 Oct 2026 08:00:00 -0400

330 patients randomized as of September 30, 2026, surpassing full trial enrollment target
Company reiterates prior guidance: primary endpoint data to be submitted for late-breaking presentation consideration at a major cardiovascular conference in Q2 2027
Data expected to support future marketing application submissions by Medtronic to the FDA and other global regulatory agencies

Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026

Wed, 16 Sep 2026 08:30:00 -0400

Sessions will highlight Orchestra BioMed's collaboration with Medtronic and explore the potential for AVIM Therapy to treat hypertensive heart disease in pacemaker-indicated patients and beyond

NEW HOPE, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that its investigational Atrioventricular Interval Modulation Therapy ("AVIM Therapy") will be featured in two sessions at HRX Live 2026 -- the Heart Rhythm Society's annual innovation-focused meeting taking place September 18-20, 2026, in Atlanta,

Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026

Wed, 16 Sep 2026 08:30:00 -0400

Sessions will highlight Orchestra BioMed's collaboration with Medtronic and explore the potential for AVIM Therapy to treat hypertensive heart disease in pacemaker-indicated patients and beyond

Orchestra BioMed receives $6.1M milestone payment from Vivasure deal

Tue, 15 Sep 2026 08:30:36 -0400

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced it received a $6.1 million milestone payment on Sept. 14, 2026, stemming from the acquisition of Vivasure Medical Limited by Haemonetics Corporation (NYSE: HAE).

The payment represents the first milestone installment tied to the transaction and follows an approximately $5 million upfront payment received in January 2026. Combined, the two payments bring total cash proceeds received by Orchestra BioMed to approximately $11 million.

Haemonetics completed its acquisition of Vivasure, an Ireland-based medical device company focused on percutaneous vessel closure technology, on Jan. 9, 2026. Vivasure had been a strategic holding of Orchestra BioMed since the

Orchestra BioMed receives $6.1M milestone payment from Vivasure deal

Tue, 15 Sep 2026 08:30:36 -0400

Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics

Tue, 15 Sep 2026 08:30:00 -0400

Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 million
Company remains eligible for up to approximately $10 million in additional proceeds through future revenue earnouts
Monetization of a strategic holding provides additional capital to advance Orchestra BioMed’s pivotal programs and reflects its approach to creating value through partnerships

NEW HOPE, Pa., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with

Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics

Tue, 15 Sep 2026 08:30:00 -0400

Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 million
Company remains eligible for up to approximately $10 million in additional proceeds through future revenue earnouts
Monetization of a strategic holding provides additional capital to advance Orchestra BioMed’s pivotal programs and reflects its approach to creating value through partnerships

Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics

Tue, 15 Sep 2026 08:30:00 -0400

Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 million
Company remains eligible for up to approximately $10 million in additional proceeds through future revenue earnouts
Monetization of a strategic holding provides additional capital to advance Orchestra BioMed’s pivotal programs and reflects its approach to creating value through partnerships